Nuvectis Pharma Inc at JPMorgan Healthcare Conference Transcript
&-
Everyone. This is Elizabeth. You got and I'm a member of the JPMorgan Healthcare Investment Banking team. And it is my pleasure to welcome you all here today and to introduce our speaker of Novartis Pharma, CEO, Ron Bentsur, you take it.
Thank you very much, Elizabeth. And I want to thank JPMorgan for inviting us to present at this very important conference and I want to thank all of you here in attendance. It's a pleasure to be here. So I'm going to talk about in effect this pharma, and we're focused on precision medicine for serious conditions of unmet medical need in oncology, and I will be making some forward-looking statements. So I do encourage anyone who's interested in the Company to read our public disclosures and in particular the risk factors that appear in our 2210 K. So it's very important that you do that as you if you decide to dig in deeper. So by way of some of some key highlights. As I said, we're focused on precision medicine
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
